When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhawajah, Mona, Oger, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195775/
https://www.ncbi.nlm.nih.gov/pubmed/22096641
http://dx.doi.org/10.1155/2011/724871
_version_ 1782214160189227008
author Alkhawajah, Mona
Oger, Joel
author_facet Alkhawajah, Mona
Oger, Joel
author_sort Alkhawajah, Mona
collection PubMed
description For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
format Online
Article
Text
id pubmed-3195775
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31957752011-11-17 When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults? Alkhawajah, Mona Oger, Joel Mult Scler Int Review Article For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making. Hindawi Publishing Corporation 2011 2011-05-17 /pmc/articles/PMC3195775/ /pubmed/22096641 http://dx.doi.org/10.1155/2011/724871 Text en Copyright © 2011 M. Alkhawajah and J. Oger. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Alkhawajah, Mona
Oger, Joel
When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title_full When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title_fullStr When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title_full_unstemmed When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title_short When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
title_sort when to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195775/
https://www.ncbi.nlm.nih.gov/pubmed/22096641
http://dx.doi.org/10.1155/2011/724871
work_keys_str_mv AT alkhawajahmona whentoinitiatediseasemodifyingdrugsforrelapsingremittingmultiplesclerosisinadults
AT ogerjoel whentoinitiatediseasemodifyingdrugsforrelapsingremittingmultiplesclerosisinadults

Ejemplares similares